MedElevator Войти в исследования
← Поиск публикаций

DOI 10.1016/j.autneu.2021.102888

Медицинская библиотека · Autonomic neuroscience : basic & clinical · 2021

Symptomatic use of carbidopa in autonomic disorders.

Golden Elisabeth P, Park Christine J, Vernino Steven

СтатьяПеревод в очереди

Аннотация

Carbidopa is being explored as a novel therapy for hyperadrenergic symptoms of autonomic disorders, due to its potential to decrease peripheral catecholamine levels. This study retrospectively characterized patients in our autonomic clinic who were prescribed carbidopa for open label treatment of autonomic symptoms. 23 patients were included; approximately half had postural orthostatic tachycardia syndrome. Those with documented plasma catecholamines had elevated standing norepinephrine. Patients typically had multiple comorbidities and multiple failed therapies. 19 took carbidopa (typically 25 mg three times daily); 12 continued it for longer than 3 months. 11 patients reported better symptom control with carbidopa, most commonly tremor and gastrointestinal dysfunction. 4 patients reported side effects. In this small retrospective study, carbidopa was well tolerated in patients with dysautonomia, and half reported symptomatic benefit. Larger, placebo-controlled trials are warranted for further investigation of this therapy.

Для цитирования: Golden Elisabeth P, Park Christine J, Vernino Steven. Symptomatic use of carbidopa in autonomic disorders.. Autonomic neuroscience : basic & clinical. 2021. DOI: 10.1016/j.autneu.2021.102888.

Предметные рубрики MeSH

Подготовка и перевод публикации
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…

История · было → стало

Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.

Тип публикации указан по данным источника. Уровень доказательности автоматически не присваивается.